These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

324 related items for PubMed ID: 9267461

  • 1. High incidence of secondary myelodysplastic syndromes following PROMACE-MOPP and involved field radiotherapy for localized gastric non-Hodgkin's lymphomas.
    Corti C, Theodore C, Bayle C, Rougier P, Nasr F, Cosset JM, Girinsky T, Hayat M, Ribrag V.
    Hematol Oncol; 1996 Dec; 14(4):159-63. PubMed ID: 9267461
    [Abstract] [Full Text] [Related]

  • 2. [Second neoplasms as a late complication of the treatment of Hodgkin's disease].
    Morales MD, González FA, Villegas A, del Potro E, Díaz Mediavilla J, Martínez R, Alvarez A, Colomé JA.
    Sangre (Barc); 1992 Dec; 37(6):429-33. PubMed ID: 1293793
    [Abstract] [Full Text] [Related]

  • 3. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
    Harrison CN, Gregory W, Hudson GV, Devereux S, Goldstone AH, Hancock B, Winfield D, MacMillan AK, Hoskin P, Newland AC, Milligan D, Linch DC.
    Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
    [Abstract] [Full Text] [Related]

  • 4. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809.
    Fisher RI, Dana BW, LeBlanc M, Kjeldsberg C, Forman JD, Unger JM, Balcerzak SP, Gaynor ER, Roy V, Miller T.
    J Clin Oncol; 2000 May; 18(10):2010-6. PubMed ID: 10811664
    [Abstract] [Full Text] [Related]

  • 5. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E, Anselmo AP, Klersy C, Santoro M, Orlandi E, Pagnucco G, Lunghi F, Maurizi-Enrici R, Baroni CD, Lazzarino M, Mandelli F, Bernasconi C.
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B, Jancić-Nedeljkov R, Sretenović M, Milivojević G, Janković S, Petrović M.
    Srp Arh Celok Lek; 1998 Sep; 126(9-10):345-8. PubMed ID: 9863405
    [Abstract] [Full Text] [Related]

  • 8. Intermediate and high-grade gastric non-Hodgkin's lymphoma: a prospective study of non-surgical treatment with primary chemotherapy, with or without radiotherapy.
    Haim N, Leviov M, Ben-Arieh Y, Epelbaum R, Freidin N, Reshef R, Ben-Shahar M.
    Leuk Lymphoma; 1995 Apr; 17(3-4):321-6. PubMed ID: 8580802
    [Abstract] [Full Text] [Related]

  • 9. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.
    Josting A, Wiedenmann S, Franklin J, May M, Sieber M, Wolf J, Engert A, Diehl V, German Hodgkin's Lymphoma Study Group.
    J Clin Oncol; 2003 Sep 15; 21(18):3440-6. PubMed ID: 12668650
    [Abstract] [Full Text] [Related]

  • 10. Long-term outcome of localized high-grade non-Hodgkin's lymphoma treated with high dose CHOP regimen and involved field radiotherapy: results of a GOELAMS study.
    Bernard M, Cartron G, Rachieru P, LeMevel A, Branger B, Le Maignan C, Berthou C, Ghandour C, Delwail V, Milpied N, Cassasus P, Celigny PS, Guyotat D, Lamy T, Desablens B, French GOELAMS Group.
    Haematologica; 2005 Jun 15; 90(6):802-9. PubMed ID: 15951293
    [Abstract] [Full Text] [Related]

  • 11. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
    Schenkein DP, Roitman D, Miller KB, Morelli J, Stadtmauer E, Pecora AL, Cassileth P, Fernandez H, Cooper BW, Kutteh L, Lazarus HM.
    Biol Blood Marrow Transplant; 1997 Oct 15; 3(4):210-6. PubMed ID: 9360783
    [Abstract] [Full Text] [Related]

  • 12. Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study.
    Moser EC, Noordijk EM, van Leeuwen FE, Baars JW, Thomas J, Carde P, Meerwaldt JH, van Glabbeke M, Kluin-Nelemans HC.
    Haematologica; 2006 Nov 15; 91(11):1481-8. PubMed ID: 17043014
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen.
    Yamanaka R, Shinbo Y, Sano M, Homma J, Tsuchiya N, Yajima N, Tamura T, Hondoh H, Takahashi H, Morii K, Onda K, Tanaka R.
    Leuk Lymphoma; 2007 Jun 15; 48(6):1119-26. PubMed ID: 17577775
    [Abstract] [Full Text] [Related]

  • 15. [Clinical analysis of reactive thymic hyperplasia following chemotherapy for childhood malignant lymphoma].
    Zhen ZJ, Sun XF, Xia Y, Wang ZH, Ling JY.
    Ai Zheng; 2006 Apr 15; 25(4):471-5. PubMed ID: 16613683
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. New treatment options have changed the survival of patients with follicular lymphoma.
    Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP.
    J Clin Oncol; 2005 Nov 20; 23(33):8447-52. PubMed ID: 16230674
    [Abstract] [Full Text] [Related]

  • 20. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG, Ghirardelli ML, Avanzini P, Baldini L, Quarta G, Stelitano C, Broglia C, Loni C, Silingardi V, Ascari E.
    Haematologica; 2000 Mar 20; 85(3):263-8. PubMed ID: 10702814
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.